智利科兴疫苗的结果出来了
- 主题发起人 eetimes
- 开始时间
- 注册
- 2007-01-19
- 消息
- 28,903
- 荣誉分数
- 9,897
- 声望点数
- 373
这不是打疫苗，是纳鞋底子！建议每周打一针，估计10周后有效率能上90%。
- 注册
- 2012-09-04
- 消息
- 64,310
- 荣誉分数
- 11,629
- 声望点数
- 1,373
美国是因为开放了，不往上冲就不错了，看看加拿大，疫苗打的少，一波强劲反弹。
什么叫变节，我只是在最初引用过一次100有效的说法。但是那也没错，我当时认为疫苗只要能产生抗体就是有效。 后来知道这里有效率的定义完全不是我想的那样。此后我再没有说过哪个疫苗更有效地话。全部都是对你发表的论据的非议。争论基本上都在疫苗的安全性上。我自始至终的观点都是mRNA疫苗是长期安全性不如灭火疫苗明朗或者说明确。事实也是如此。根据我所看到的报导，副作用方面灭活疫苗应该是最低的。
我觉得你们高兴的太早，离全面评价各种疫苗还远。新增病例大趋势上应该和疫苗有效率成某种比例关系，但是其他因素太多，科学上不构成充分条件。安全性问题更是没有科学的评估的基础。例如AZ的血栓问题渐渐的浮出水面。
别着急，让子弹飞一会儿。跳的太高容易让天花板撞断脖子。
- 注册
- 2008-05-09
- 消息
- 34,253
- 荣誉分数
- 7,814
- 声望点数
- 373
一句话：没人知道...
贵圈
政府都对党
- 注册
- 2014-10-21
- 消息
- 32,821
- 荣誉分数
- 6,152
- 声望点数
- 373
100%有效无害，没法蹦得更高了。也就到这了。sorry什么叫变节，我只是在最初引用过一次100有效的说法。但是那也没错，我当时认为疫苗只要能产生抗体就是有效。 后来知道这里有效率的定义完全不是我想的那样。此后我再没有说过哪个疫苗更有效地话。全部都是对你发表的论据的非议。争论基本上都在疫苗的安全性上。我自始至终的观点都是mRNA疫苗是长期安全性不如灭火疫苗明朗或者说明确。事实也是如此。根据我所看到的报导，副作用方面灭活疫苗应该是最低的。
我觉得你们高兴的太早，离全面评价各种疫苗还远。新增病例大趋势上应该和疫苗有效率成某种比例关系，但是其他因素太多，科学上不构成充分条件。安全性问题更是没有科学的评估的基础。例如AZ的血栓问题渐渐的浮出水面。
别着急，让子弹飞一会儿。跳的太高容易让天花板撞断脖子。
- 注册
- 2005-11-23
- 消息
- 30,321
- 荣誉分数
- 7,459
- 声望点数
- 373
PFIZER-BIONTECH ANNOUNCE POSITIVE TOPLINE RESULTS OF PIVOTAL COVID-19 VACCINE STUDY IN ADOLESCENTS
Wednesday, March 31, 2021 - 06:45am- In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated
- The companies plan to submit these data to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as soon as possible to request expansion of the Emergency Use Authorization (EUA) and EU Conditional Marketing Authorization for BNT162b2
- The companies also provided an update on the Phase 1/2/3 study of BNT162b2 in children aged 6 months to 11 years
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents | Pfizer
In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated The companies plan to submit these data to the U.S. Food and Drug...
贵圈
政府都对党
- 注册
- 2014-10-21
- 消息
- 32,821
- 荣誉分数
- 6,152
- 声望点数
- 373
打两针灭活疫苗保护率达100%：国产新冠疫苗预计12月底上市-凉山新闻网
100% 保护率
- 注册
- 2008-05-09
- 消息
- 34,253
- 荣誉分数
- 7,814
- 声望点数
- 373
牛，太牛了！PFIZER-BIONTECH ANNOUNCE POSITIVE TOPLINE RESULTS OF PIVOTAL COVID-19 VACCINE STUDY IN ADOLESCENTS
Wednesday, March 31, 2021 - 06:45am
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated. These are topline results from a pivotal Phase 3 trial in 2,260 adolescents.
- In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated
- The companies plan to submit these data to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as soon as possible to request expansion of the Emergency Use Authorization (EUA) and EU Conditional Marketing Authorization for BNT162b2
- The companies also provided an update on the Phase 1/2/3 study of BNT162b2 in children aged 6 months to 11 years
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents | Pfizer
In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated The companies plan to submit these data to the U.S. Food and Drug...www.pfizer.com
贵圈
政府都对党
- 注册
- 2014-10-21
- 消息
- 32,821
- 荣誉分数
- 6,152
- 声望点数
- 373
PFIZER-BIONTECH ANNOUNCE POSITIVE TOPLINE RESULTS OF PIVOTAL COVID-19 VACCINE STUDY IN ADOLESCENTS
Wednesday, March 31, 2021 - 06:45am
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated. These are topline results from a pivotal Phase 3 trial in 2,260 adolescents.
- In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated
- The companies plan to submit these data to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as soon as possible to request expansion of the Emergency Use Authorization (EUA) and EU Conditional Marketing Authorization for BNT162b2
- The companies also provided an update on the Phase 1/2/3 study of BNT162b2 in children aged 6 months to 11 years
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents | Pfizer
In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated The companies plan to submit these data to the U.S. Food and Drug...
什么破玩意，不信，我只信国药集团的灭活！中国药业可信度贼高。100%可信！打死也不用洋人的疫苗！
相关推荐
